Top entities: Paragon Therapeutics, United States — Food and Drug Administration, Kessler Topaz Meltzer & Check, Darren Ngasseu Nkamga, United States — United States District Court for the Southern District of California.

What category does this event fall under?

Regulatory — classified as securities fraud.

What is the sentiment of coverage?

Aggregate sentiment score: -60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Darren Ngasseu Nkamga filed lawsuit Paragon Therapeutics · United States — Food and Drug Administration released briefing documents · United States — Food and Drug Administration disagreed with changes Paragon Therapeutics

Is this event still developing?

This is an active story, last updated Aug 16, 2026. Coverage continues to evolve.

Regulatory securities fraud

Capricor Securities Fraud Class Action Filed

Q: When did this event occur?

First reported Aug 14, 2026; last updated Aug 16, 2026.

Q: What is the market impact?

General. The disclosure of FDA disagreement and unfavorable benefit-risk assessment caused Capricor's stock to plummet 64%, reflecting severe negative market sentiment.

Analysis based on 6 articles · First reported Aug 14, 2026 · Last updated Aug 16, 2026

Sentiment

-60

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The disclosure of FDA disagreement and unfavorable benefit-risk assessment caused Capricor's stock to plummet 64%, reflecting severe negative market sentiment. The securities fraud lawsuit adds legal and reputational risk, potentially further depressing investor confidence and the company's market valuation.

Biotechnology Pharmaceuticals

Event Summary

A securities fraud class action lawsuit has been filed against Paragon Therapeutics, Inc. (NASDAQ: CAPR) in the United States — United States District Court for the Southern District of California, captioned Darren Ngasseu Nkamga v. Paragon Therapeutics, Inc., No. 26-cv-04385. The suit alleges that Capricor made materially false and misleading statements and omissions regarding changes to the pre-specified statistical analysis plan for its lead product candidate Deramiocel and failed to obtain FDA agreement before resubmitting the Biologics License Application (BLA). On July 27, 2026, the FDA released briefing documents ahead of an advisory committee meeting, revealing that Capricor had changed the statistical analysis plan without prior FDA review or agreement. The FDA stated it did not consider the conversion of raw change to percent change and back to raw change scientifically justified, and that the benefit-risk assessment for Deramiocel appeared unfavorable in the absence of evidence of effectiveness. Following this news, Capricor's stock fell 64%. The law firm Kessler Topaz Meltzer & Check, LLP is publicizing the lawsuit and encouraging affected investors to contact them, with a lead plaintiff deadline of September 28, 2026.

Key Actions

90 Darren Ngasseu Nkamga filed lawsuit Paragon Therapeutics

85 United States — Food and Drug Administration released briefing documents

80 United States — Food and Drug Administration disagreed with changes Paragon Therapeutics

75 Paragon Therapeutics changed statistical analysis plan

70 Paragon Therapeutics announced advisory meeting United States — Food and Drug Administration

30 Kessler Topaz Meltzer & Check informs investors

Entities Involved

priv

Paragon Therapeutics

Capricor is the defendant in the securities fraud class action and the subject of FDA scrutiny over its statistical analysis plan changes for Deramiocel. The stock fell 64% following FDA briefing documents, and the lawsuit compounds its legal and financial risks.

Importance 100.0 Sentiment -90.0

govactor

United States — Food and Drug Administration

The FDA released briefing documents and disagreed with Capricor's statistical analysis plan changes, stating the benefit-risk assessment for Deramiocel appears unfavorable. This regulatory action is central to the stock drop and the lawsuit.

Importance 80.0 Sentiment 10.0

priv

Kessler Topaz Meltzer & Check

The law firm is publicizing the class action and encouraging investors to contact them, positioning itself to represent plaintiffs. This enhances its profile in securities litigation but does not directly affect its financials.

Importance 60.0 Sentiment 20.0

per

Darren Ngasseu Nkamga

As the named plaintiff in the class action, Nkamga represents the class of investors who purchased Capricor securities during the class period. His role is to seek recovery for alleged losses.

Importance 50.0 Sentiment 0.0

govactor

United States — United States District Court for the Southern District of California

The court is the venue for the securities fraud class action lawsuit, which will determine the legal outcome. Its role is procedural and does not directly affect its own standing.

Importance 40.0 Sentiment 0.0

per

Jonathan Naji

Jonathan Naji is the attorney at Kessler Topaz Meltzer & Check, LLP handling investor inquiries. His role is to facilitate communication and potential representation for affected investors.

Importance 30.0 Sentiment 0.0

Relationships

Paragon Therapeutics related ↔ United States — Food and Drug Administration

Kessler Topaz Meltzer & Check related ↔ Jonathan Naji

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard